Given a QuantiFERON‑TB Gold test with TB‑1 antigen minus nil 1.03 IU/mL, TB‑2 antigen minus nil 0.72 IU/mL, mitogen minus nil 8.27 IU/mL, and nil 0.17 IU/mL, what is the likelihood of Mycobacterium tuberculosis infection?

QuantiFERON-TB Gold Test Interpretation: POSITIVE Result

Based on your QuantiFERON-TB Gold test results (TB1-Nil = 1.03 IU/mL, TB2-Nil = 0.72 IU/mL), you have a POSITIVE test indicating Mycobacterium tuberculosis infection. The likelihood of TB infection is high, as both antigen responses exceed the diagnostic threshold of 0.35 IU/mL 1, 2.

Test Result Analysis

Your specific values demonstrate:

• TB1 antigen minus nil: 1.03 IU/mL (POSITIVE - well above 0.35 cutoff)
• TB2 antigen minus nil: 0.72 IU/mL (POSITIVE - well above 0.35 cutoff)
• Mitogen minus nil: 8.27 IU/mL (adequate positive control response)
• Nil: 0.17 IU/mL (acceptable background, well below 8.0 threshold)

Both TB antigen responses are clearly positive by FDA-approved criteria. The QFT-GIT assay is considered positive when the IFN-γ response to Mtb antigens minus the nil control is ≥0.35 IU/mL 1. Your results substantially exceed this threshold in both tubes, eliminating any interpretive uncertainty.

Clinical Significance

Your test indicates established Mycobacterium tuberculosis infection. Research demonstrates that IFN-γ values >0.7 IU/mL are consistent with established Mtb infection, with 87% of active TB patients showing values in this range 3. Both your TB1 (1.03) and TB2 (0.72) responses fall into or exceed this category, strengthening confidence in true infection rather than borderline variability.

The robust response in both antigen tubes (TB1 and TB2) is particularly significant. Studies show that 97% of individuals with latent TB infection respond to both tubes, compared to only 81% of those with active TB 4. Your dual positive response pattern is more consistent with latent infection than active disease, though clinical evaluation remains essential.

Key Interpretation Points

Valid test controls:

• Your mitogen response (8.27 IU/mL) confirms adequate T-cell function
• Your nil value (0.17 IU/mL) is appropriately low, ruling out high background interference
• The test is NOT indeterminate (which would require mitogen ≤0.5 or nil >8.0) 1

No borderline uncertainty:

• Values between 0.2-0.7 IU/mL represent a "borderline zone" where test variability can occur 5, 3
• Your TB1 value (1.03) is well above this zone
• Your TB2 value (0.72) just exceeds this zone but combined with TB1 provides definitive interpretation
• The substantial elevation in TB1 eliminates concerns about technical variability

Clinical Action Required

You require clinical evaluation to distinguish between latent TB infection (LTBI) and active TB disease:

1. Immediate assessment needed for active TB symptoms:

   • Persistent cough >2-3 weeks
   • Fever, night sweats, weight loss
   • Hemoptysis or chest pain
   • If symptomatic: chest X-ray and sputum testing mandatory

2. If asymptomatic:

   • Chest X-ray to exclude active pulmonary TB
   • Clinical history for TB exposure risk factors
   • Assessment for LTBI treatment eligibility

3. Treatment considerations:

   • LTBI treatment prevents progression to active disease (5-10% lifetime risk if untreated)
   • Treatment decision based on risk factors, age, comorbidities, and medication contraindications

Important Caveats

This test does NOT distinguish between latent and active TB - clinical and radiographic evaluation is mandatory 1. The positive IGRA indicates immune response to TB antigens but requires correlation with symptoms, imaging, and epidemiologic risk factors.

False positives are rare but possible with cross-reactivity from M. kansasii, M. szulgai, or M. marinum infection 1, 2, though these are uncommon causes.

Your test should not be repeated for confirmation given the clearly positive results well above diagnostic thresholds. Serial testing is only indicated for borderline results or conversion monitoring in high-risk populations 3.